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Summary 
Background: During the 2015/16 influenza season in Europe, the co-circulating influenza viruses 
were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata 
component in the trivalent influenza vaccine. 
 
Methods: We used the test negative design in a multicentre case–control study in twelve European 
countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically-attended 
influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a 
systematic sample of consulting ILI patients and a random sample of influenza positive swabs were 
sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic 
group 6B.1 and influenza B overall and by age group. 
 
Results: We included 11,430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 
were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). 
Among those aged 0–14, 15–64 and ≥65  years VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3-
65.0), 41.4% (95%CI: 20.5-56.7) and 13.2% (95% CI: -38.0-45.3) respectively. Overall VE against 
influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95%CI: -4.1-56.7). Among those aged 0–14, 
15–64 and ≥65 years VE against influenza B was -47.6% (95%CI: -124.9-3.1), 27.3% (95%CI: -4.6-
49.4), and 9.3% (95%CI: -44.1-42.9) respectively.  
 
Conclusions: VE against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in 
children and adults, and low among individuals ≥65  years. VE against influenza B was low and 
heterogeneous among age groups. More information on effects of previous vaccination and previous 
infection are needed to understand the VE results against influenza B in the context of a mismatched 
vaccine. 
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Introduction 
In February 2015 WHO recommended that the 2015/16 Northern Hemisphere trivalent influenza 
vaccine should include the same influenza A(H1N1)pdm09 strain as the 2014/15 season vaccine (the 
same component for the trivalent vaccine since the 2010/11 season), but different influenza 
A(H3N2) and B components, namely a virus from the 3C.3a A(H3N2) genetic group and the genetic 
group 3 of the B/Yamagata lineage. The recommended strains were: an influenza 
A/California/7/2009 (H1N1)pdm09-like virus, an influenza A/Switzerland/9715293/2013 (H3N2)-like 
virus, and  an influenza B/Phuket/3073/2013-like Yamagata lineage virus. 
An interim analysis for the 2015/16 season published in early February 2016 from the European I-
MOVE/I-MOVE+ multicentre case control study showed a predominance of A(H1N1)pdm09 (71%, 
246/348), with influenza B co-circulating (22%; 77/348) among participating study sites 1. Among the 
B specimens where lineage information was available, 97.3% (36/37) were of the B/Victoria lineage, 
indicating a mismatch with the influenza B/Yamagata virus included in the trivalent vaccine.  
In this eighth season of the I-MOVE/I-MOVE+ multicentre case-control study we aimed to measure 
end-of-season 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09 and influenza B, by 
age group, vaccine type, by prior (2014/15) vaccination status, and by time since vaccination, for the 
total population and the target group for vaccination. 
Nine of twelve study sites also participated in a pilot laboratory project where they randomly 
selected specimens for sequencing of at least the gene segment coding for the haemagglutinin, in 
order to compute a representative VE estimate against the influenza A(H1N1)pdm09 6B.1 genetic 
group. 
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Methods 
Twelve European study sites located in Croatia, France, Germany, Hungary, Ireland, Italy, Poland, 
Portugal, Romania, Spain, Sweden and the Netherlands participated in the test-negative 2015/16 
multicentre case-control study. The methods have been described previously 2–4 and are based on 
the ECDC generic case-control study protocol and the I-MOVE+ protocol 5,6. 
Participating practitioners interviewed and collected naso-pharyngeal or combined naso- and oro-
pharyngeal specimens from a systematic sample of consenting patients seeking medical attention 
for influenza like illness (ILI). In Hungary, only patients aged 18 years and older and in Croatia only 
patients aged 65 years and older were eligible. Practitioners collected in a standardised report form 
information including symptoms, date of onset and swabbing, 2015/16 seasonal vaccination status, 
date of influenza vaccination and vaccine product, prior (2014/15) seasonal vaccination status, sex, 
age and presence of chronic medical conditions in the past 12 months.  
Seven study sites included a question on belonging to the target group for vaccination. In France, 
Germany, Poland, Portugal and Sweden the target group was defined from patients’ information on 
age, chronic conditions and pregnancy. Additionally, in Portugal, being a health professional or carer 
and a co-habitant or carer of a patient at-risk aged less than six months and in Poland, belonging to 
an occupational risk group (e.g. healthcare worker), defined the target group. 
In the pooled analysis we included patients meeting the European Union ILI case definition 7, 
swabbed within seven days of symptom onset, and who had not received antivirals in the 14 days 
prior to swabbing.  
A case of confirmed influenza was an ILI patient who was swabbed and tested positive for influenza 
virus using real-time reverse-transcription polymerase chain reaction (RT-PCR). Controls were ILI 
patients who tested negative for any influenza virus using RT-PCR. 
We defined a person as vaccinated if he or she had received at least one dose of a 2015/16 seasonal 
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influenza vaccine more than 14 days before ILI symptom onset. Those vaccinated less than 15 days 
before ILI onset were excluded. All other patients were classified as unvaccinated. 
For each study site we included ILI patients presenting more than 14 days after the start of national 
or regional influenza vaccination campaigns and we excluded controls presenting before the onset 
week of the first influenza type/subtype-specific case. ILI patients presenting in weeks of onset after 
two or more consecutive weeks of no cases and influenza A cases that were not further subtyped 
were also excluded from the analysis. 
For each study site, we computed the odds ratio (OR) of being vaccinated in cases vs. controls. We 
conducted a complete analysis excluding patients with missing values for any of the variables in the 
model measuring adjusted VE. Using Cochran's Q-test and the I2 index we tested the heterogeneity 
between study sites 8. We estimated the pooled type/subtype influenza VE as (1 minus the OR)*100 
using a one-stage model with study site as a fixed effect.  
Using a logistic regression model we calculated VE including potential confounding factors: date of 
symptom onset (modelled as a restricted cubic spline with 4 knots where sample size allowed), age 
(modelled as a restricted cubic spline with 4 knots or age groups depending on the analysis), sex, and 
presence of at least one chronic medical condition (including pregnancy and obesity where 
available).We used the one in ten rule of predictor degrees of freedom to events to determine the 
maximum number of covariates to include in analyses with low sample sizes in order to avoid 
overfitting the model 9,10. 
To study the effect of prior (2014/15) vaccination on the 2015/16 VE, we conducted an indicator 
analysis using four categories: individuals unvaccinated in both seasons (reference category), 
vaccinated in 2014/15 only, vaccinated in 2015/16 only, and those vaccinated in both seasons. We 
did not measure effect of prior (2014/15) vaccination among children aged <9 years as their 
vaccination definition is based on previous vaccination history (children older than 6 months and less 
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than 9 years old who have not been vaccinated in the previous influenza season should receive two 
doses of the seasonal influenza vaccine). We also conducted a stratified analysis, measuring VE of 
the 2015/16 vaccine among those vaccinated in 2014/15 and separately among those not vaccinated 
in 2014/15. 
 
We measured VE by age-group (0-14, 15-64 and 65 years and older), by type of vaccine (inactivated 
subunit and inactivated split virion) and in the target group for vaccination. We tested for interaction 
between vaccination and age group, chronic medical condition, onset month and sex, using the 
likelihood ratio test to compare the additive model with the interaction. 
To study the effects of waning of the vaccine effect within a season, we further estimated VE by time 
since vaccination, modelling days between vaccination and symptom onset dates as a restricted 
cubic spline with 4 knots 11. In this analysis we additionally included patients vaccinated 14 days or 
less before symptom onset (excluded from the main analysis). 
Nine study sites participated in a laboratory pilot project (DE, FR, HU, IE, PT, RO, SE, ES and NL) for 
sequencing at least the haemagglutinin gene segment for each influenza type/subtype. In this 
laboratory pilot project either all specimens were selected for sequencing or a proportion of 
specimens were randomly selected for sequencing to ensure representativity. The proportion of 
specimens randomly selected for sequencing could vary over time (e.g. higher early in the season 
and lower during the peak) and a sampling fraction was calculated for each study site and time unit.  
The specimens were sent to the corresponding National Influenza Centre, where influenza diagnosis 
was confirmed and viruses characterised by sequencing the HA1 coding portion of the 
haemagglutinin gene. Analysis of the nucleotide and amino acid sequences of the HA1 coding 
portion of the haemagglutinin gene were performed in MEGA6 to determine clade distribution. 
We weighted the genetic group-specific VE analysis using the reciprocal of the sequencing sampling 
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fraction for each time period and study site and used robust standard errors. 
Data management and statistical analyses were carried out using Stata 14 (StataCorp. 2015. College 
Station, TX, USA). 
Results 
The 2015/16 influenza season in Europe was characterised by the co-circulation of influenza 
A(H1N1)pdm09  and influenza B viruses (Figure 1). Influenza A(H3N2) viruses circulated at very low 
levels. The study period ranged from week 44, 2015 to week 18, 2016 for influenza A(H1N1)pdm09 
with cases peaking in week 4, 2016 and from week 45, 2015 to week 19 for influenza B, with cases 
peaking in week 9, 2016. 
Of the 14,294 ILI patients recruited, 11,430 met the eligibility criteria (5410 cases and 6020 controls). 
In the influenza type/subtype specific analysis 2272 cases of influenza A(H1N1)pdm09 and 2901 
cases of influenza B were included (Figure 2). We did not include the 172 patients testing positive for 
influenza A(H3N2) in the analysis due to small sample size. 
The proportion vaccinated with the 2015/16 influenza vaccine was 9.7% among controls, 6.7% 
among influenza A(H1N1)pdm09 cases and 6.3% among influenza B cases (Table 1).  
 
The median age of influenza A(H1N1)pdm09 cases was 35 years, of controls  29 years and of 
influenza B cases 12 years (Table 2). Compared to influenza A(H1N1)pdm09, a higher proportion of 
influenza B cases were less than 15 years (55.3% vs 30.3%) and a lower proportion were 15-64 years 
old (40.8% vs 63.5%). The proportion of patients aged 65 and older varied between controls, 
influenza A(H1N1)pdm09 and influenza B cases with 9.5%, 6.2% and 3.9% respectively. 
 
The proportion of patients with at least one chronic condition was similar between controls and 
influenza A(H1N1)pdm09 cases (20.2% and 17.6% respectively), but lower among influenza B cases 
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(11.9%). 
 
Among controls 81.7% were swabbed within three days of symptom onset compared to 84.9% and 
85.2% of influenza A(H1N1)pdm09 and influenza B cases, respectively. Among controls 6.5% were 
swabbed on the day of symptom onset, compared to 4.2% and 4.3% of influenza A(H1N1)pdm09 and 
influenza B cases respectively. 
 
In total, 10.6% of controls had received both the 2014/15 and the 2015/16 vaccines compared to 7.3 
and 6.2% of influenza A(H1N1)pdm09 and B cases respectively. The proportion of unvaccinated in 
the current and previous season was 89.2% for influenza A(H1N1)pdm09 cases, 90.1% for influenza B 
cases and 83.6% for controls.  
 
Information on vaccine type received was available for 470 (83.3%) of vaccinated controls, 130 
(86.7%) vaccinated influenza A(H1N1)pdm09 and 149 (82.2%) vaccinated influenza B cases. Trivalent 
inactivated subunit and trivalent inactivated split virion vaccines were used among 43.4% and 43.0% 
of vaccinated controls, 43.8% and 49.2% of vaccinated influenza A(H1N1)pdm09 cases and 45.9% 
and 48.0% of vaccinated influenza B cases respectively. 
 
From the 11,430 patients meeting the eligibility criteria, we further excluded patients with missing 
information on 2015/16 seasonal vaccination status or date, onset/swab date, age, sex or presence 
of chronic condition. We included 7358 patients for the complete case analysis of VE against 
influenza A(H1N1)pdm09 and 7400 patients for the analysis against influenza B among all ages 
(Figure 2). For the complete case analysis restricted to the target group for vaccination we included 
1953 patients (520 influenza A(H1N1)pdm09 cases) in the analysis of VE against A(H1N1)pdm09 and 
1578 patients (409 influenza B cases) in the analysis of VE against influenza B. 
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Influenza A(H1N1)pdm09 
Statistical heterogeneity between VE estimates against influenza A(H1N1)pdm09 by study site was 
low overall (among all ages) and among those aged 15-64 years (I2 index 0% and 10% respectively). 
Due to small sample sizes it was not possible to estimate heterogeneity among other age groups. 
The adjusted VE in the total population (all ages) against influenza A(H1N1)pdm09 was 32.9% (95% 
CI: 15.5-46.7) (Table 2). The adjusted VE against influenza A(H1N1)pdm09 was 31.9% (95% CI: -32.3-
65.0) among the 0-14 year olds and 41.4% (95% CI: 20.5-56.7) among the 15-64 year olds. Among 
the target group for vaccination VE (all ages) was 33.0% (95% CI: 10.8-49.7). It was 55.5% (95% CI: -
35.1-85.3) and 42.9% (95% CI: 14.5-61.9) among those aged 0-14 and 15-64 years respectively. 
Among those aged 65 years and older VE adjusted for age and study site was 13.2% (95%CI: -38.0-
45.3). 
 
The adjusted VE for trivalent inactivated subunit vaccine against influenza A(H1N1)pdm09 (all ages) 
was 33.9% (95% CI: 6.7-53.1) and for trivalent inactivated split virion vaccine 36.9% (95% CI: 10.8-
54.5) (Table 2).  
 
Information on prior vaccination status was missing among 6.7% of ILI patients (restricting to those 
nine years and older).  When using the indicator analysis, with the reference of those not vaccinated 
in the current or previous season, the VE among those aged 9 years and older against influenza 
A(H1N1)pdm09 for those who received 2015/16 seasonal influenza vaccine only was 54.7% (95% CI: 
19.6-74.5), 8.0 (95% CI: -39.3-39.2) for those who received prior (2014/15) vaccine only and 28.4% 
(95% CI: 6.2-45.4) for those who received both 2015/16 and 2014/15 season vaccine (Table 2).  
 
In the stratified analysis, the VE of current influenza vaccination against A(H1N1)pdm09 among 
those aged 9 years and older was 56.2% (full model adjusted, 95% CI: 22.2-75.3) among those not 
vaccinated in 2014/15 and  6.9% (adjusted by age and study size, 95% CI: -51.5-42.8) among those 
vaccinated in 2014/15. 
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When modelling VE by time since vaccination, VE against influenza A(H1N1)pdm09 among all ages 
increased to 49.8 % at 45 days since vaccination and declined to 9.3% at 218 days since vaccination 
(Figure 3). 
 
During the study period where specimens were sequenced, the nine sites participating in the 
laboratory pilot season genetically characterised 723 of 2087 (34.6%) influenza A(H1N1)pdm09 
specimens among all ages. Of these, 15 (2.1%) belonged to the genetic group represented by 
A/England/377/2015 (genetic group 6B.2), 56 (7.7%) to the genetic group represented by 
A/SouthAfrica/3626/2013 (genetic group 6B) and 652 (90.2%) to the genetic group represented by 
A/Slovenia/2903/2015 (genetic group 6B.1)(Table 3). The adjusted VE against 6B.1 was 32.8% (95% 
CI: -4.1-56.7) overall for all age groups, 51.3% (95% CI: -33.5-82.3) among the 0-14 year old and 
40.1% (95% CI: -12.9-68.3) among 15-64 year old age groups (Table 2). The sample size was too small 
to calculate VE for those aged 65 years and older. 
 
Influenza B 
The I2 index for heterogeneity between VE estimates against influenza B by study site was 56% 
among all ages and 0% among those aged 15-64 years. Due to small sample size it was not possible 
to estimate heterogeneity among those aged 65 years and older. Among children we could measure 
the I2 between three countries (DE, FR, IT; in all other countries less than 5 children were 
vaccinated), which was 0%. 
The adjusted VE against influenza B was -47.6% (95% CI: -124.9-3.1) among the 0-14 year olds and 
27.3% (95% CI: -4.6-49.4) among the 15-64 year olds (Table 2). Crude VE was 9.3% (95% CI: -44.1-
42.9) among those aged 65 years and older (all belong to the target group for vaccination only), and 
the small sample size did not allow for adjusted VE estimates. The Chi2 of the likelihood ratio test for 
interaction between vaccine and age group was 24.0 (p<0.001). Due to this strong interaction 
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between age group and vaccine we did not attempt to calculate an overall (all ages) VE. The adjusted 
VE among the target group for vaccination was 1.7% (95% CI: -94.5-50.3) and 38.4% (95% CI: -6.6-
64.4) among those aged 0-14 years and 15-64 years respectively. 
The adjusted VE for trivalent inactivated subunit vaccine against influenza B among those aged 0-14 
years was -56.4% (95% CI: -202.1-19.0) and for split virion vaccine -83.5% (95% CI: -232.9--1.1) (Table 
3). For those aged 15-64 years it was 17.7% (95% CI: -48.0-54.3) for subunit vaccine and 44.4% (95% 
CI: -2.8-70.0) for split virion vaccine. 
 
Information on prior vaccination status was missing in 5.1% of ILI patients (restricting to those nine 
years and older). When using the indicator analysis, with the reference of those not vaccinated in 
the current or previous season, the VE among 15-64 year olds receiving the current 2015/16 
seasonal influenza vaccine only was 28.3% (95% CI: -40.2-63.3), 41.3 (95% CI: -8.7-68.3) among those 
receiving prior season (2014/15) vaccine only and 23.7% (95% CI: -16.8-50.2) among those who 
received both 2015/16 and prior season (2014/15) vaccine (Table 2).  
In the stratified analysis, the VE of current influenza vaccination against influenza B among 15-64 
year olds was 28.7% (95% CI: -39.6-63.5) among those who did not receive prior season (2014/15) 
vaccine.  We could not compute VE of current influenza vaccination among those who received prior 
season (2014/15) due to small sample size.  
 
When modelling VE by time since vaccination among those aged 15 years and older, VE against 
influenza B ranged from 2.3% at 218 days to 36.6% at 60 days (Figure 3). 
 
Of the 2901 influenza B cases (all ages), 2132 (73.5%) had known B/lineage. Among these, 2.7% were 
B/Yamagata lineage (57) and 97.3% were B/Victoria lineage (2075). Among the 8/9 pilot lab study 
sites that sequenced B positive specimens 321/2416 were sequenced (13.3%)(Table 3). Twelve 
(3.7%) belonged to the genetic group represented by B/Phuket/3073/2013 (Yamagata lineage) group 
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3. Among the 309 (96.3%) that belonged to the genetic group represented by B/Brisbane/60/2008 
(Victoria lineage), all belonged to genetic group 1A, and 308 of them had N129D amino acid 
substitutions, and one had K56N and V124A amino acid substitutions.  
Discussion 
The 2015/16 influenza VE against medically attended ILI due to influenza A(H1N1)pmd09 in the I-
MOVE/I-MOVE+ multicentre case-control study in Europe ranged from 13.2-55.5% in the total and 
target population, depending on age group. There was a very low VE or no protective effect against 
influenza B among 0-14 year olds and VE among 15-64 year olds among the total and target 
population ranged from 27.3-38.4%. 
In the 2015/16 season twelve study sites contributed to the I-MOVE multicentre case control study 
and 11430 individuals were included. This is the largest sample size since the network began in 
2008/09. The number of vaccinated patients remains low, even among the target group for 
vaccination, with 29-30% of controls vaccinated. Despite the large sample size, this results in a 
reduced precision, which is one of the limitations of the study. 
VE point estimates against influenza A(H1N1)pdm09 were lower in 2015/16 than in 2014/15, overall 
and by each age group (54.2, 73.1, 59.7 and 22.4 for all ages, 0-14 year olds, 15-59 year olds and 
those aged 60 and older respectively). VE point estimates against A(H1N1)pdm09 were also lower in 
Canada and in the US, compared to 2013/14, the last year where influenza A(H1N1)pdm09 was a 
dominant or co-dominant circulating strain in these countries 12–15. We observed a low influenza 
A(H1N1)pdm09 VE point estimate among those aged 65 years and older that was not seen in other 
studies in 2015/16 14,16,17. However in our study the number of individuals in this age group was low 
and VE was only adjusted by age and study site.  
The results suggest a decrease in VE with time since vaccination against influenza A(H1N1)pdm09 
across this long and late season. While the decrease is mild and precision around the estimate is low, 
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this is the first season where we observed this decrease in  influenza A(H1N1)pdm09 VE 11. A decline 
in VE against influenza A(H1N1)pdm09 with time across the season was also suggested in the 
2015/16 season in Canada 12. However more research on the effects of immunity along the season 
and the in-season decline in VE would be useful to validate the results. 
In the 2014/15 season, the influenza A(H1N1)pdm09 genetic group 6B dominated and in 2015/16 a 
major genetic variant, 6B.1, defined by the HA1 amino acid substitutions S84N, S162N and I216T 
emerged. For the sites participating in the pilot laboratory project, 90.2% of all sequenced influenza 
A(H1N1)pdm09 specimens belonged to the 6B.1 genetic group. Antigenic characterisation by 
haemaglutinin inhibition (HI) assay of circulating influenza A(H1N1)pdm09 viruses from EU/EEA 
countries using ferret sera indicated that they were antigenically similar to the vaccine virus 18. 
However 6B.1 viruses were poorly inhibited by some post-vaccination human serum pools and WHO 
recommends an influenza A/Michigan/45/2015 (H1N1)pdm09-like virus (6B.1 genetic group) for the 
2017 southern hemisphere influenza vaccine 19.  It is possible that the lower VE point estimate 
against influenza A(H1N1)pdm09 in the I-MOVE/I-MOVE+ study in 2015-16 may be linked to the 
changes in the circulating strain compared to the vaccine strain.  
The VE point estimate against influenza A(H1N1)pdm09 for those receiving 2015/16 season vaccine 
only was higher than that among those receiving both 2014/15 and 2015/16  vaccines. While the 
two estimates are never statistically different from each other, the pattern looks like those from the 
negative interference hypothesis: that interference from previous season vaccine may be present 
when consecutive season vaccine components are similar and there is a large antigenic distance 
between the circulating and vaccine strain 20. The 2015/16 and 2014/15 influenza A(H1N1)pdm09 
vaccine strains were identical,  however more evidence is needed to determine the antigenic 
distance between the vaccine strain (A/California/7/2009 (H1N1)pdm09-like virus) and the 6B.1 
circulating genetic group. This pattern was not seen in the 2014/15 season, where vaccine strains 
were identical and the circulating strain was the 6B genetic group (current and prior season VE point 
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estimates: 47.2% and 52.7% respectively) 21. Alternative and also likely explanations for the 2015/16 
results may be random variation due to a low vaccination coverage and confounding due to different 
participant profiles of repeat and single season vaccinees. 
The VE point estimate of subunit vaccine against influenza A(H1N1)pdm09 was higher than that of 
split virion among 0-14 year olds, but the same among 15-59 year olds. However precision is low due 
to small numbers of vaccinated. Age-specific VE estimates for vaccine groups are not available in 
previous I-MOVE study publications and would be useful going forward, numbers of vaccinated 
allowing. 
This is the first season in which the I-MOVE study could provide representative VE estimates against 
an influenza genetic group. This represents great progress, although precision around the age-
stratified estimates is low. In the 2015/16 season there was only one major genetic group 
circulating. In seasons where two or more genetic clades are co-circulating, more sequencing is 
needed to obtain a reasonable precision. Precise genetic group-specific estimates provide important 
information for interpreting overall VE results and VE results by time since vaccination. 
The VE against influenza B was very low or may have conferred no protection among children and 
was low to moderate among 15-64 year olds. The differences in VE between age groups were large 
(p<0.001). In the context of this effect modification and different age distributions between studies, 
due to different healthcare seeking behaviours and practitioners included in the study (France, Italy, 
Germany and Spain include paediatricians in the study), providing a VE among all ages was not 
appropriate. The age-specific effect modification and differential age distribution may explain in part 
why the heterogeneity of study site specific estimates among all ages was moderate to high 
(I2=55.9%).  
In the UK and the US the 2015/16 VE against influenza B among children was higher than in the I-
MOVE/I-MOVE+ multicentre case control study. The VE was 56.3% in the UK among those children 
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receiving the (predominantly trivalent) inactivated injectable vaccine, and in the US 64% against 
B/Yamagata and 56% against B/Victoria among those children receiving the (predominantly 
quadrivalent) inactivated injectable vaccine 14,17. A low VE among children was seen in Finland 
receiving the (predominantly trivalent) inactivated injectable vaccine (-1%)22. In the US, there is a 
universal vaccination recommendation, in the UK and Finland, vaccine is recommended in certain 
age groups in children, However, in the countries participating in the I-MOVE/I-MOVE+ multicentre 
case control study vaccine is recommended only to children with chronic conditions, with the 
exception of Poland where vaccination is recommended among those aged 6 months to 18 years 23–
25. 
The low VE against influenza B in children in the I-MOVE/I-MOVE+ multicentre case control study in 
the 2015/16 season is in contrast to 2014/15 where VE against influenza B was 62.1% (95%CI: 14.9 
to 83.1) 21. While a selection bias among children could explain the low VE against influenza B, the 
higher VE against influenza A(H1N1)pdm09 among children (31.9%) and the high VE in the 2014/15 
season suggest otherwise. Few children in the 2015/16 study were vaccinated with the quadrivalent 
vaccine (4.4% among those vaccinated children with known vaccine product). 
 
The crude VE against influenza B in those aged 65 years and older was low as observed in the UK (-
20.2%), in Danish interim estimates (4.1%; hospital-based patients included), and in the US (-34%; B 
Flannery, personal communication, 8th March 2017) 2015-16 season 16,17. 
 
In the 2015/16 season, the circulating strains were antigenically distinct from the strain selected for 
the influenza B component in the trivalent influenza vaccine. Nevertheless there was VE of 27.3% 
among 15-64 year olds. Varying levels of cross-protection have been reported previously 26–28. In the 
2015/16  season, our VE point estimates are less than 10% among those aged 0-14 years and those 
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aged 65 years and above. Among older adults and children, the differences observed in VE in a 
season of mismatch between the vaccine and circulating strains may be explained by a combination 
of immune system properties specific to children and the elderly, as well as by the role of previous 
vaccinations and previous infections. 
The VE point estimate was higher for subunit vaccine than for split virion vaccine among children, 
but precision was low. Both estimates were low, indicating that the low VE was not due to a vaccine 
type-specific issue. Among 15-64 year olds, split virion VE point estimate was higher than subunit 
vaccine, but again precision was low. 
In our study there is residual protection of the prior (2014/15) season vaccine against influenza B 
among 15-64 year olds. The 2014/15 trivalent vaccine also contained a B/Yamagata virus, 
mismatched with regards to the lineage circulating in 2015/16.  Vaccination in current and previous 
season resulted in a similar VE against influenza B among 15-59 year olds as vaccination with current 
vaccine only.  
In the 2015/16 influenza season the results of I-MOVE/I-MOVE+ study suggest a lower VE against 
influenza A(H1N1)pdm09 and influenza B than in previous seasons. Both the low VE against influenza 
B in children and older adults and the low to moderate VE against influenza B among younger adults 
may be important in the context of cost-effectiveness studies looking into recommendations for 
quadrivalent vaccines and the need for more precise data need to be collected. Lower VE against 
influenza A(H1N1)pdm09 in the 2015/16 season, as well as the indications of the effects of previous 
vaccination seen here and elsewhere need to be evaluated in subsequent seasons together with 
virological and immunological results. 
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Figures 
Figure 1: Number of influenza-like illness (ILI) reports by case status, week of symptom onset and influenza 
virus type/sub-type, total population, I-MOVE/I-MOVE+ multicentre case control study, influenza season 
2015/16, weeks 35/2015 – week 20/2016 (study period with influenza positive cases: week 41/2015-
week 19/2016) 
Figure 2. Flowchart of data exclusion for pooled analysis. I-MOVE/I-MOVE+ multicentre case control 
study, influenza season 2015/16 (week 41/2015-week 19/2016) 
Figure 3: Adjusted VE and 95% CI against influenza A(H1N1)pdm09 (all ages) and influenza B (15 
years and older) by time since vaccination, total population, I-MOVE/I-MOVE+ multicentre case control 
study, influenza season 2015/16 (week 41/2015-week 19/2016) 
 
Tables 
Table 1: Details for influenza A(H1N1)pdm09 (n=22721) and influenza B cases (n=2901) and controls 
(n=1650) included in the 2015/16 season influenza vaccine effectiveness analysis (week 41/2015-
week 19/2016), I-MOVE/I-MOVE+ multicentre case control study. 
Table 2. Pooled crude and adjusted seasonal vaccine effectiveness against laboratory confirmed 
influenza by influenza type/suptype and A(H1N1)pdm09 genetic group 6B.1, overall , by age groups, 
by previous vaccination status and the target group for vaccination. I-MOVE/I-MOVE+ multicentre 
case control study, influenza season 2015/16 (week 41/2015-week 19/2016). 
Table 3. Influenza A(H1N1)pdm09, influenza B/Yamagata and influenza B/Victoria viruses 
characterised by clade and study site, study sites participating in the laboratory pilot study, I-
MOVEmulticentre case control study, Europe, influenza season 2015/6 (week 41/2015 - week 
16/2016). 
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Table 1: Details for influenza A(H1N1)pdm09 (n=2272) and influenza B cases (n=2901) and controls 
(n=1650) included in the 2015/16 season influenza vaccine effectiveness analysis (week 41/2015-
week 19/2016), I-MOVE/I-MOVE+ multicentre case control study. 
Variables 
Number of test-
negative controls 
a/total n(%) 
 
Number of influenza 
A(H1N1)pdm09/total 
n(%) 
Number of 
influenza B cases 
/total n(%) 
Median age (years) 29.0 35.0 12.0 
Age groups     
0-4 1437/6004 (23.9) 365/2268 (16.1) 536/2894 (18.5) 
5-14 739/6004 (12.3) 321/2268 (14.2) 1064/2894 (36.8) 
15-64 3255/6004 (54.2) 1441/2268 (63.5) 1182/2894 (40.8) 
≥ 65 573/6004 (9.5) 141/2268 (6.2) 112/2894 (3.9) 
Missing 16 4 7 
Sex    
Female 3159/5975 (52.9) 1137/2259 (50.3) 1456/2871 (50.7) 
Missing 45 13 30 
Days between onset of 
symptoms and swabbing 
   
0 389/6020 (6.5) 95/2272 (4.2) 126/2901 (4.3) 
1 2008/6020 (33.4) 824/2272 (36.3) 907/2901 (31.3) 
2 1589/6020 (26.4) 663/2272 (29.2) 899/2901 (31.0) 
3 934/6020 (15.5) 348/2272 (15.3) 539/2901 (18.6) 
4-7 1100/6020 (18.3) 342/2272 (15.1) 430/2901 (14.8) 
Seasonal vaccination,  
2015/16 564/5802 (9.7) 150/2223 (6.7) 180/2841 (6.3) 
Vaccinated <15 days before 
onset of symptoms 
17 0 0 
Missing 201 49 60 
Prior season influenza 
vaccinationb    
Not vaccinated in any season 3259/3896 (83.6) 1421/1593 (89.2) 1481/1635 (90.1) 
Current season (2015/16) 
vaccination only 87/3896 (2.2) 17/1593 (1.1) 19/1635 (1.2) 
Prior (2014/15)  season 
vaccination only 138/3896 (3.5) 39/1593 (2.4) 33/1635 (2.0) 
Current and prior season 
vaccination 412/3896 (10.6) 116/1593 (7.3) 102/1635 (6.2) 
Missing or vaccinated <15 days 
before onset 279 109 69 
Seasonal vaccination type    
Not vaccinated  5255/5819 (90.3) 2073/2203 (93.3) 2661/2809 (93.7) 
Inactivated subunit 204/5819 (3.5) 57/2203 (2.6) 68/2809 (2.4) 
Inactivated split virion trivalent 202/5819 (3.5) 64/2203 (2.9) 71/2809 (2.5) 
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Variables 
Number of test-
negative controls 
a/total n(%) 
 
Number of influenza 
A(H1N1)pdm09/total 
n(%) 
Number of 
influenza B cases 
/total n(%) 
Adjuvantedc 60/5819 (1.0) 6/2203 (0.3) 6/2809 (0.2) 
Inactivated  cell derived 
subunit  1/5819 (0.0) 0/2203 (0.0) 0/2809 (0) 
Quadrivalent vaccine d 3/5819 (0.1) 3/2203 (0.1) 3/2809 (0.1) 
Unknown vaccine type 94/5819 (1.6) 20/2203 (0.9) 32/2809 (1.1) 
Missing vaccination status or 
date or vaccinated <15 days 
before onset 81 49 60 
At least one chronic condition 1194/5900 (20.2) 391/2227 (17.6) 341/2870 (11.9) 
Missing 120 45 31 
At least one hospitalisation in 
the previous 12 months for 
chronic conditions 110/5857 (1.9) 26/2214 (1.2) 21/2854 (0.7) 
Missing 163 58 47 
Belongs to the target group 
for vaccination 1648/5931 (27.8) 544/2236 (24.3) 434/2873 (15.1) 
Missing 89 36 28 
Study sites    
Croatia 39/6020 (0.6) 15/2272 (0.7) 19/2901 (0.7) 
France 1471/6020 (24.4) 508/2272 (22.4) 1294/2901 (44.6) 
Germany 1726/6020 (28.7) 436/2272 (19.2) 571/2901 (19.7) 
Hungary 593/6020 (9.9) 54/2272 (2.4) 112/2901 (3.9) 
Ireland 241/6020 (4.0) 181/2272 (8) 130/2901 (4.5) 
Italy 498/6020 (8.3) 34/2272 (1.5) 390/2901 (13.4) 
Poland 312/6020 (5.2) 136/2272 (6.0) 65/2901 (2.2) 
Portugal 186/6020 (3.1) 111/2272 (4.9) 11/2901 (0.4) 
Romania 80/6020 (1.3) 61/2272 (2.7) 0/2901 (0.0) 
Spain 286/6020 (4.8) 447/2272 (19.7) 165/2901 (5.7) 
Sweden 376/6020 (6.2) 175/2272 (7.7) 65/2901 (2.2) 
The Netherlands 212/6020 (3.5) 114/2272 (5.0) 79/2901 (2.7) 
    
 
a Controls for “any influenza” used here (number of controls differ slightly for influenza 
A(H1N1)pdm09 and B analyses, due to the inclusion criteria). 
b Among patients aged 9 years and over. 
c  Includes Squalene (MF59), virosome and aluminium phosphate gel adjuvants. 
d includes Fluenz tetra (nasal spray) as well as Fluarix tetra (injectable). 
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Table 2. Pooled crude and adjusted seasonal vaccine effectiveness against laboratory confirmed 
influenza by influenza type/suptype and A(H1N1)pdm09 genetic group 6B.1, overall , by age groups, 
by previous vaccination status and the target group for vaccination. I-MOVE/I-MOVE+ multicentre 
case control study, influenza season 2015/16 (week 41/2015-week 19/2016) 
 
Type/subty
pe 
Analysis scenario 
 
Na 
Cases;vacc / 
Controls; vacca 
Crud
e 
VEa,b 
CI 
Adjust
ed VEc 
CI 
A(H1N1)pd
m09 d 
 All ages 
735
8 
2176;148 / 5182;527 41.9 
28.9-
52.6 
32.9 15.5-46.7 
 
By age 0-14 y 
242
4 
648;14 / 1776;56 25.4 
-39.1-
60.0 
31.9 
-32.3-
65.0 
 
 15-64 y 
430
8 
1394;73 / 2914;230 40.8 
21.1-
55.6 
41.4 20.5-56.7 
 
 65+ y 625 134;61 / 491;240 26.8 
-14.4-
53.1 
13.2e 
-38.0-
45.3 
 
Target group for 
vaccination 
All ages 
195
3 
520;114/1433;425 44.3 
27.4-
57.2 
33.0 10.8-49.7 
  0-14 y 253 70;6/183;24 48.7 
-46.7-
82.1 
55.5f 
-35.1-
85.3 
  15-64 y 
106
1 
315;47/746;155 45.2 
18.9-
62.9 
42.9 14.5-61.9 
 
By vaccine type –all 
ages 
Unvaccinated (ref) 
668
3 
2028/4655     
  Subunit vaccine 242 57/185 39.3 
16.2-
56.1 
33.9 6.7-53.1 
  Split virion vaccine 255 62/193 47.6 
28.6-
61.5 
36.3 10.8-54.5 
 
By vaccine type –0-14 
year olds 
Unvaccinated (ref) 
235
4 634/1720 Ref 
   
  Subunit vaccine 
24 4/20 46.2 
-68.5-
82.8 51.1 
-55.8-
84.6 
  Split virion vaccine 
28 6/22 7.6 
-144.8-
65.1 16.3 
-137.2-
70.4 
 
By vaccine type –15-
64 year olds 
Unvaccinated (ref) 
400
5 1321/2684 Ref 
   
  Subunit vaccine 112 27/85 43.5 9.9-64.6 45.6 12.1-66.4 
  Split virion vaccine 
106 28/78 45.7 
14.2-
65.6 45.2 11.8-65.9 
 
By prior (2014/15) 
influenza vaccination 
status – ≥9 year olds 
Neither 
437
8 
1404/2974 Ref  Ref  
  2015/16 season only 100 17/83 
59.2 
28.8-
76.6 54.7 19.6-74.5 
  
2014/15 season only 
 
146 38/108 
19.0 
-20.3-
45.5 8.0 
-39.3-
39.2 
  Study and previous season 497 114/383 
43.0 
28.0-
54.9 28.4 6.2-45.4 
 
By prior (2014/15) 
influenza vaccination 
status – ≥9 year olds, 
target group 
Neither 
110
6 
335/771 
      
  2015/16 season only 67 10/57 
66.5 
30.8-
83.8 60.4 16.0-81.3 
  
2014/15 season only 
 
85 14/71 
53.6 
12.8-
75.3 46.4 -2.4-72.0 
  Study and previous season 428 95/333 
46.4 
28.0-
60.1 31.8 5.7-50.7 
 
By prior (2014/15) 
influenza vaccination 
Neither 
370
7 
1244/2483     
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status – 15-64 year 
olds 
  2015/16 season only 66 10/56 70.3 
39.5-
85.4 
68.2 34.4-84.6 
  
2014/15 season only 
 
102 30/72 11.0 
-40.1-
43.4 
12.7 
-38.9-
45.1 
  Study and previous season 220 58/162 32.4 6.5-51.2 32.1 4.2-51.8 
 
A(H1N1)pdm09 clade 
6B.1 
All ages 
477
9 
645;46/4134;434 45.5 
18.4-
63.5 
32.8 -4.1-56.7 
 0-14 y 
150
5 
191;5/1314;43 38.6 
-74.8-
78.4 
51.3 
-33.5-
82.3 
 15-64 y 
284
0 
417;19/2423;197 42.5 
-8.2-
69.4 
40.1 
-12.9-
68.3 
  
65+ years (Sample size too 
small) 
406 36;22/370;189     
Influenza Bf By age 0-14 y 
330
4 
1545;82 / 1759;52 
-
81.4 
-159.2--
26.9 
-47.6 
-124.9-
3.1 
 
 15-64 y 
360
6 
1138;49 / 2468;196 46.4 
25.4-
61.5 
27.3 -4.6-49.4 
 
 65+ y 488 104;46 / 384;186 9.3 
-44.1-
42.9   
 
Target group for 
vaccination 
0-14 y 326 141;34/185;27 
-
21.3 
-121.0-
33.4 
1.7g 
-94.5-
50.3 
  15-64 y 751 163;22/588;121 46.8 
11.4-
68.1 
38.4 -6.6-64.4 
 By vaccine type 
0-14 year olds 
 
Unvaccinated 
(ref) 
317
0 
1463/1707     
   Subunit vaccine 50 31/19 
-
93.7 
-246.0--
8.4 -56.4 
-202.1-
19.0 
   
Split virion 
vaccine 
67 44/23 
-
106.
9 
-245.0--
24.1 -83.5 
-232.9--
1.1 
  
15-64 year olds 
 
Unvaccinated 
(ref) 
336
1 
1089/2272     
   Subunit vaccine 89 17/72 
47.1 8.4-69.4 17.7 
-48.0-
54.3 
   
Split virion 
vaccine 
84 15/69 
57.9 
25.2-
76.3 44.4 -2.8-70.0 
 
By prior (2014/15) 
influenza vaccination 
status 
15-64 year olds Neither 
319
4 
1055/2139     
   
2015/16 
season only 
59 13/46 37.8 
-17.1-
67.0 
28.3 
-40.2-
63.3 
   
2014/15 
season only 
77 16/61 49.1 
10.0-
71.2 
41.3 -8.7-68.3 
   Both seasons 176 35/141 49.0 
24.8-
65.4 
23.7 
-16.8-
50.2 
a Based on the complete case analysis: records with missing age, sex, chronic condition, vaccination status are dropped) 
b Crude VE adjusted by study site. 
C Data adjusted for age (restricted cubic spline or age group), onset date (restricted cubic spline), sex, chronic condition and 
study site unless otherwise indicated. 
d Study sites included in A(H1N1)pdm09 all ages and ≥9 years analysis: DE,ES,FR,HR,HU,IE,IT,NL,PL,PT,RO,SE; HU and HR not 
included in A(H1N1)pdm09 0-14 years analysis; HR not included in A(H1N1)pdm09 15-64 years analysis; Study sites 
included in A(H1N1)pdm09 clade 6B.1 analysis all ages and 15-64 year olds: DE,ES,FR,HU,IE,NL,PT,RO,SE; HU not included in 
A(H1N1)pdm09 clade 6B.1 0-14 years analysis; Study sites included in B 0-14 years analysis: DE,ES,FR,IE,IT,NL,PL,PT,SE ; 
Study sites included in B 15-64 years analysis: DE,ES,FR,HU,IE,IT,NL,PL,PT,SE; Study sites included in B 65 years and older 
analysis: DE,ES,FR,HR,HU,IE,IT,NL,PL,SE 
e Adjusted by age and study site only. 
f Due to heterogeneity of VE estimates against influenza B between age groups, no “all ages” estimate against influenza B 
was attempted. 
g Adjusted by time and study site only. 
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Table 3. Influenza A(H1N1)pdm09, influenza B/Yamagata and influenza B/Victoria viruses 
characterised by clade and study site, study sites participating in the laboratory pilot study, I-
MOVEmulticentre case control study, Europe, influenza season 2015/6 (week 41/2015 - week 
16/2016). 
 
Characterised viruses 
Genetic 
group 
DE FR HU IE PT RO ES SE NL 
Total 
(%) 
Influenza A(H1N1)pdm09            
A/England/377/2015 6B.2 3 8 0 0 0 2 1 1 0 15 
(2.1) 
A/SouthAfrica/3626/2013 6B 4 1 1 1 12 2 30 0 5 56 
(7.7) 
A/Slovenia/2903/2015 6B.1 143 83 19 15 76 27 245 20 24 652 
(90.2) 
Total  150 92 20 16 88 31 276 21 29 723 
Influenza B            
B/Phuket/3073/2013 3 11 0 0 0 - - 0 1 0 12 
(3.7) 
B/Brisbane/60/2008 1A 135 85 32 5 - - 9 15 28 309 
(96.3) 
Total  146 85 32 5 - - 9 16 28 321 
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